Drug
YM 155
YM 155: highest development phase Phase 1/2, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| YM 155 NCT00514267 | Phase 1/2 | Prostate Cancer |
Latest
No recent events.
Follow YM 155 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.